JWH-309

JWH-309

0JWH-309 is a synthetic cannabinoid from the JWH series. It was developed by the team of John W. Huffman at Clemson University. It is a research chemical that acts as a potent agonist for the cannabinoid receptors.

History

The JWH series was developed in the mid-1990s by Huffman and his team in an effort to create a new class of cannabinoids for the treatment of pain and inflammation. JWH-309 is one of the many compounds in this series.

Chemistry

JWH-309 is a synthetic cannabinoid, which means it is not naturally occurring but is instead created in a laboratory. It is structurally similar to other synthetic cannabinoids in the JWH series. The chemical formula for JWH-309 is C24H23NO.

Pharmacology

JWH-309 acts as a potent agonist for the cannabinoid receptors, specifically the CB1 receptor and CB2 receptor. These receptors are part of the endocannabinoid system, which plays a role in a variety of physiological processes including pain sensation, mood, and memory.

Legal Status

The legal status of JWH-309 varies by country. In many places, it is considered a controlled substance due to its potential for abuse and addiction. However, because it is a research chemical, it may be legal in some jurisdictions for research purposes.

See Also

• JWH-018
• JWH-073
• JWH-200
• Synthetic cannabinoids
• Cannabinoid receptor

‎

‎